Royalty Pharma plc (Nasdaq: RPRX) has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE